ASST shorts ease as borrow market loosens
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
ASST heads into the back half of October with its borrow market substantially looser than it was a month ago, even as the stock remains 10% below its one-month peak and analysts keep pushing their targets higher.
The lending picture has shifted sharply since early October. Through most of September and into early October, availability was at zero, meaning every share in the lending pool was already lent out, the tightest possible condition. That has changed fast. Availability has rebounded to just under 30% of short interest, and the cost to borrow has fallen by more than a quarter over the past week to around 1.09%. Short interest itself has dropped 15.6% over the past month and 8.7% over the past week alone, landing at 3.1% of the free float. The combination tells a coherent story: shorts have been covering, and as they returned stock to lenders, availability opened back up. Borrowing costs followed. The borrow market that looked extraordinarily tight a fortnight ago now looks merely snug. Options positioning adds a mild caution signal. The put/call ratio has drifted up to 0.44, above its 20-day average of 0.34, placing it about 1.3 standard deviations above recent norms. That is elevated but nowhere near the 52-week high of 1.08, so the options market looks more guarded than alarmed.
The Street remains firmly bullish, though the debate about how this company actually makes money has not gone away. Every analyst on the register carries a Buy rating, and Maxim Group raised its target from $21 to $37 on October 12, a 76% jump. B. Riley Securities has lifted its target twice since early September, most recently to $33. The mean analyst target of $38.80 sits 43% above the current price of $27.06, an unusually wide gap that reflects both genuine enthusiasm and uncertainty about the valuation path. The company's own fundamentals are hard to read on conventional metrics. Q2 revenues were $2.9M against operating costs of $24.4M, and the reported net loss of $258.2M was dominated by an unrealized mark-to-market loss on Bitcoin holdings. The bull case rests on accretive BTC-per-share growth through preferred equity issuance: the company acquired 6,236 BTC in the quarter, ended with 19,864 BTC, and delivered a 23.9% BTC Yield alongside 44 consecutive business days of SATA preferred dividends. The bear case is that the entire model depends on Bitcoin appreciation and continued access to capital markets on favourable terms, with operating revenue barely covering a fraction of overhead.
The institutional register has some weight behind it. FMR added 2.7 million shares in the most recently reported period, lifting its stake to 11.6% of shares. BlackRock added 1.6 million shares to reach 6.2%. Founder and CEO Vivek Ramaswamy held 6.7% as of early October. The top three holders between them account for roughly a quarter of all shares, which concentrates the ownership picture considerably and leaves the stock exposed to shifts in any of those positions.
Past earnings prints have not moved the stock dramatically. The last four results produced a one-day move of between minus 3.3% and plus 1.1%, with five-day drifts of 3.5% to 10.7% in each case. No next earnings date is currently scheduled. What to watch from here is whether short interest continues declining toward the lower bound of recent ranges, and whether the reopening of borrow availability attracts fresh short positioning or simply reflects a one-time wave of covering.
Stocks in this article
See the live data behind this article on ORTEX.
Open ASST on ORTEX →How this article was generated
- Generated
- 21 Oct 2026, 21:09
- Data as of
- 21 Oct 2026, 21:08
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.